This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis (BMS-AZPCOS)

This study has been completed.
Information provided by (Responsible Party):
Karen Elkind-Hirsch, Woman's Identifier:
First received: December 17, 2013
Last updated: October 31, 2016
Last verified: October 2016
The objective of the present proposal is to compare the clinical, endocrine and metabolic effects of therapy with combination saxagliptin and metformin to saxagliptin and metformin monotherapy in women with PCOS and prediabetic hyperglycemia (IFG, IGT or IFG/IGT). Saxagliptin is an oral dipeptidyl peptidase IV (DPP-4) inhibitor whose mechanism of action is to prolong the duration of blood glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels by inhibiting their degradation and thereby augmenting insulin secretion. This study will serve as a pilot investigation to open perspectives for future studies to explore the potential of combining anti-diabetic drugs with different mechanisms of action in in patients with PCOS and impaired glucose regulation (IGR), especially ones for whom standard treatment with metformin is less effective.

Condition Intervention Phase
Polycystic Ovary Syndrome Disorder of Glucose Regulation Drug: Metformin XR Drug: Saxagliptin Drug: Saxagliptin-Metformin XR Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Metabolic and Endocrine Effects of Combination of Metformin and DPP4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study

Resource links provided by NLM:

Further study details as provided by Karen Elkind-Hirsch, Woman's:

Primary Outcome Measures:
  • Fasting and 2 hour glucose levels after glucose load [ Time Frame: Change from baseline to 16 weeks ]
    Correcting glucose control as evaluated by fasting and 2 hour glucose levels after an OGTT

  • Surrogate measures of insulin sensitivity and secretion [ Time Frame: Change from baseline to 16 weeks ]
    Improving markers of insulin sensitivity and secretion after an oral glucose load as measured by the Matsuda index and early insulin response adjusted for insulin sensitivity (insulinogenic index/HOMA-IR).

  • ß-cell compensatory function [ Time Frame: Change from baseline to 16 weeks ]
    Improving ß-cell compensatory function by enhancing insulin release after an oral glucose load and thus improve or delay a decline in glucose tolerance estimated by the disposition index defined as the product of insulin action (Matsuda index) and insulin secretion (insulinogenic index) derived from the OGTT (SIOGTT x Δinsulin30-0 min to glucose30-0 min).

Secondary Outcome Measures:
  • Cardiometabolic risk factors [ Time Frame: Change from baseline to 16 weeks ]
    We will further examine whether addition of saxagliptin therapy to metformin is more beneficial than either drug alone in altering the development or progression of select cardiometabolic risk factors as measured by changes in lipids and blood pressure

  • Free androgen index [ Time Frame: Change in baseline to 16 weeks ]
    We will further examine whether the administration of combined metformin and saxagliptin therapy is more beneficial than saxagliptin or metformin alone in improving hyperandrogenism as measured by improvements in total testosterone and/or SHBG

Other Outcome Measures:
  • Liver enzymes [ Time Frame: Change from baseline to 16 weeks ]
    SubjeThe safety criteria will include incidence and intensity of adverse events, physical exams, vital signs and laboratory values (liver enzymes).

Enrollment: 38
Study Start Date: March 2014
Study Completion Date: October 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Metformin XR
Metformin 2000 mg QD for 16 weeks
Drug: Metformin XR

Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks

Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study

Other Names:
  • Glucophage XR
  • Biguanide-insulin sensitizer
Active Comparator: Saxagliptin
Saxagliptin 5 mg QD for 16 weeks
Drug: Saxagliptin

Start 1 pill (5 mg)) for 3 weeks

Remain at 1 pill (5mg dose) for remainder of study

Other Names:
  • Onglyza
  • DPP-4 inhibitor
Experimental: Saxagliptin-Metformin XR

Saxagliptin-Metformin XR (combination pill)

5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks

Drug: Saxagliptin-Metformin XR

Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks

Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study

Other Names:
  • Kombiglyze XR
  • Combination DPP-4 inhibitor and Glucophage XR

  Show Detailed Description


Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females 18 years to 42 years of age with PCOS (NIH criteria) with prediabetic hyperglycemia determined by an 75 gram oral glucose tolerance test (OGTT). Study subjects will be inclusive of PCOS women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT).
  • Written consent for participation in the study

Exclusion Criteria:

  • Presence of significant systemic disease, heart problems including congestive heart failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)
  • Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology), gallstones, abnormal liver function tests or renal impairment (elevated serum creatinine levels or abnormal creatinine clearance)
  • Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital adrenal hyperplasia or hyperprolactinemia
  • Significantly elevated triglyceride levels (fasting triglyceride > 400 mg %)
  • Untreated or poorly controlled hypertension (sitting blood pressure > 160/95 mm Hg)
  • Use of hormonal medications, drugs known to affect gastrointestinal motility, lipid-lowering (statins, etc.) and/or anti-obesity drugs or medications that interfere with carbohydrate metabolism (such as isotretinoin, hormonal contraceptives, GnRH analogues, glucocorticoids, anabolic steroids, C-19 progestins) for at least 8 weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as 5-alpha reductase inhibitors (finasteride, spironolactone, flutamide) for at least 4 weeks
  • Prior history of a malignant disease requiring chemotherapy
  • Known hypersensitivity or contraindications to use of insulin sensitizers such as metformin or thiazolidinediones
  • History of hypersensitivity reaction to saxagliptin or other DPP-4 inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions)
  • Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, or weight loss medications (prescription or OTC) Patients must stop use of insulin sensitizers or antidiabetic medicines such as metformin for at least 4 weeks or thiazolidinediones, GLP1 agonists or DPPIV inhibitors for 8 weeks.
  • Prior use of medication to treat diabetes except gestational diabetes
  • Use of drugs known to exacerbate glucose tolerance
  • Eating disorders (anorexia, bulimia) or gastrointestinal disorders
  • Suspected pregnancy (documented negative serum ßhCG test), desiring pregnancy during the study treatment interval, breastfeeding, or known pregnancy in last 2 months
  • Active or prior history of substance abuse (smoke or tobacco use within past 3 years) or significant intake of alcohol or history of alcoholism
  • Patient not willing to use adequate barrier contraception during study period (unless sterilized or have an IUD).
  • Debilitating psychiatric disorder such as psychosis or neurological condition that might confound outcome variables
  • Inability or refusal to comply with protocol
  • Not currently participating or having participated in an experimental drug study in previous three months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02022007

United States, Louisiana
Woman's Hospital
Baton Rouge, Louisiana, United States, 70817
Sponsors and Collaborators
Principal Investigator: Karen Elkind-Hirsch, Ph.D. Woman's Hospital, Louisiana
  More Information

Responsible Party: Karen Elkind-Hirsch, Director of Research, Woman's Identifier: NCT02022007     History of Changes
Other Study ID Numbers: RP13-013
BMS CV181-354 ( Other Grant/Funding Number: Bristol Myers Squibb/Astra Zaneca )
Study First Received: December 17, 2013
Last Updated: October 31, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Karen Elkind-Hirsch, Woman's:
DPP-4 inhibitor

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Physiological Effects of Drugs
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on June 27, 2017